Bacillus pumilus Microorganism for Gastric Juice Secretion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic gastritis, particularly those caused by Helicobacter pylori infection, lack non-toxic gastric-acid promoters that can effectively enhance gastric juice secretion and prevent associated ulcers and cancer.

Innovation Solution

A novel microorganism of the species Bacillus pumilus, which is non-toxic and promotes gastric juice secretion, is discovered. It has properties that include increasing platelet, erythrocyte, and leukocyte counts, and can be cultivated and stored for use in therapeutic applications, with secretory products extracted and tested for efficacy in animal models.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drugs (gastric-acid secretion blockers, gastric antacids, mucoprotective agents) are used to treat peptic ulcers and chronic gastritis, then the defense mechanisms are reinforced and digestive fluids are suppressed, but gastric-acid secretion is not promoted and the underlying cause of chronic gastritis is not addressed

Engineering Contradiction:

Improveeffectiveness in treating chronic gastritisVSAvoidlack of gastric-acid promotion and failure to address underlying cause

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies this principle by using a beneficial microorganism (Bacillus pumilus) that can coexist with and counteract the harmful H. pylori bacteria. The microorganism converts the harmful gastric environment into a beneficial one by promoting gastric-acid secretion and producing antibacterial substances that eliminate H. pylori, thereby treating chronic gastritis at its root cause rather than merely suppressing symptoms

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs a microorganism as an intermediary agent between the host and the harmful H. pylori bacteria. This microorganism acts as a mediator that promotes gastric-acid secretion, produces antibacterial substances, and enhances the host's natural defense mechanisms, thereby indirectly combating H. pylori infection and treating chronic gastritis without directly confronting the pathogen

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If gastric-juice promoters are developed to treat chronic gastritis, then gastric-acid secretion is enhanced, but toxicity to living organisms may occur

Engineering Contradiction:

Improveeffectiveness in promoting gastric-acid secretionVSAvoidtoxicity to living organisms

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by changing the fundamental parameter of the treatment approach from chemical drugs to a living microorganism. The microorganism naturally produces gastric-acid-promoting substances and antibacterial compounds, and its safety profile is demonstrated through toxicity tests showing LD50 values greater than 5000 mg/kg, thereby achieving effective gastric-acid promotion without toxic side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs this principle by using a microorganism that self-regulates its metabolic activities to promote gastric-acid secretion and produce antibacterial substances. The microorganism adapts to the gastric environment and naturally maintains beneficial levels of gastric acid while eliminating H. pylori, without requiring external control or posing toxicity risks

Inventive Principle:

Principle #25Self-service

3Reliability

If H. pylori infection is present, then chronic gastritis is engendered leading to ulcers and cancer, but no microorganism has been discovered that can improve gastric condition while being a kindred microbe

Engineering Contradiction:

Improveability to improve gastric conditionVSAvoidlack of kindred microbe that can coexist and counteract H. pylori

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies this principle by discovering a microorganism (Bacillus pumilus) that can coexist with H. pylori in the gastric environment and convert the harmful situation into a beneficial one. The microorganism produces antibacterial substances that specifically target and eliminate H. pylori while promoting gastric-acid secretion and improving overall gastric health, thereby transforming the harmful co-infection scenario into a therapeutic opportunity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP2196533B9Novel microorganism having gastric juice promoting action and composition secreted by the same

Publication Date: 2014.10.29 KAMEYAMA YOSHICHIKA

Figure 1~2
Figure 3
Figure 4

AI summary

Designed to afford a novel microorganism promoting gastric juice secretion and having platelet increasing activity, and to afford a pharmaceutical agent composed of a product secreted by the novel microorganism. The novel microorganism, international deposit number: NITE BP-295, belongs to the species Bacillus pumilus, and is characterized by taking either form of coccus and bacillus, and makes figure-eight movement. The novel microorganism of the present invention is the novel microorganism having the gene represented by SEQ ID No: 1, and an object of the present invention is to afford the microorganism and a gastric juice secretion-promoting composition composed of the product secreted by the novel microorganism.